Fulphila is a fillip for Biocon’s fortunes

The recent US launch of Biocon’s Fulphila (pegfilgrastim-jmdb) biosimilar co-developed with Mylan led the Indian firm’s Biologics sales to more than double to Rs3.67 billion (US$50.0 million) in its financial second quarter ended 30 September 2018.